spacer
spacer

PDBsum entry 1fn4

Go to PDB code: 
protein Protein-protein interface(s) links
Immune system PDB id
1fn4

 

 

 

 

Loading ...

 
JSmol PyMol  
Contents
Protein chains
211 a.a. *
218 a.a. *
Waters ×136
* Residue conservation analysis
PDB id:
1fn4
Name: Immune system
Title: Crystal structure of fab198, an efficient protector of acetylcholine receptor against myasthenogenic antibodies
Structure: Monoclonal antibody against acetylcholine receptor. Chain: a, c. Monoclonal antibody against acetylcholine receptor. Chain: b, d
Source: Rattus norvegicus. Norway rat. Organism_taxid: 10116. Organism_taxid: 10116
Biol. unit: Dimer (from PQS)
Resolution:
2.80Å     R-factor:   0.198     R-free:   0.294
Authors: K.Poulas,E.Eliopoulos,E.Vatzaki,J.Navaza,M.Kontou
Key ref:
K.Poulas et al. (2001). Crystal structure of Fab198, an efficient protector of the acetylcholine receptor against myasthenogenic antibodies. Eur J Biochem, 268, 3685-3693. PubMed id: 11432734 DOI: 10.1046/j.1432-1327.2001.02274.x
Date:
21-Aug-00     Release date:   26-Sep-01    
PROCHECK
Go to PROCHECK summary
 Headers
 References

Protein chains
Pfam   ArchSchema ?
P01835  (KACB_RAT) -  Ig kappa chain C region, B allele from Rattus norvegicus
Seq:
Struc:
106 a.a.
211 a.a.*
Protein chains
Pfam   ArchSchema ?
P20760  (IGG2A_RAT) -  Ig gamma-2A chain C region from Rattus norvegicus
Seq:
Struc:
322 a.a.
218 a.a.*
Key:    PfamA domain  Secondary structure  CATH domain
* PDB and UniProt seqs differ at 14 residue positions (black crosses)

 

 
DOI no: 10.1046/j.1432-1327.2001.02274.x Eur J Biochem 268:3685-3693 (2001)
PubMed id: 11432734  
 
 
Crystal structure of Fab198, an efficient protector of the acetylcholine receptor against myasthenogenic antibodies.
K.Poulas, E.Eliopoulos, E.Vatzaki, J.Navaza, M.Kontou, N.Oikonomakos, K.R.Acharya, S.J.Tzartos.
 
  ABSTRACT  
 
The crystal structure of the Fab fragment of the rat monoclonal antibody 198, with protective activity for the main immunogenic region of the human muscle acetylcholine receptor against the destructive action of myasthenic antibodies, has been determined and refined to 2.8 A resolution by X-ray crystallographic methods. The mouse anti-lysozyme Fab D1.3 was used as a search model in molecular replacement with the AMORE software. The complementarity determining regions (CDR)-L2, CDR-H1 and CDR-H2 belong to canonical groups. Loops CDR-L3, CDR-H2 and CDR-H3, which seem to make a major contribution to binding, were analyzed and residues of potential importance for antigen-binding are examined. The antigen-binding site was found to be a long crescent-shaped crevice. The structure should serve as a model in the rational design of very high affinity humanized mutants of Fab198, appropriate for therapeutic approaches in the model autoimmune disease myasthenia gravis.
 
  Selected figure(s)  
 
Figure 1.
Fig. 1. Ribbon representation of the Fab198 molecule. The molecule exhibits the typical immunoglobulin fold. The CDRs are shown in bold. (A) The molecule is shown with the variable chains (V[L]–V[H]) at the top and the constant (C[L]–C[H]) at the bottom. (B) View from the top of the molecule showing the access to the binding crevice (as in Fig. 5 Go-). The figure was prepared with MOLSCRIPT [41].
Figure 5.
Fig. 5. Top view of the antigen-binding site of the Fab198 molecule in stereo. The binding crevice is formed by residues of V[H] (in red) and V[L] (in blue). The important interacting residues are labeled in their respective colours. Black lines represent the Ca trace of VH and VL. CDRs (Ca atoms only) are represented by thick black lines and labeled (L1-L3, H1-H3). This view corresponds to Fig. 1B Go-and Fig. 6B Go-. The drawing was prepared with MOLSCRIPT [41].
 
  The above figures are reprinted by permission from the Federation of European Biochemical Societies: Eur J Biochem (2001, 268, 3685-3693) copyright 2001.  
  Figures were selected by an automated process.  

Literature references that cite this PDB file's key reference

  PubMed id Reference
19319967 M.Zouridakis, P.Zisimopoulou, K.Poulas, and S.J.Tzartos (2009).
Recent advances in understanding the structure of nicotinic acetylcholine receptors.
  IUBMB Life, 61, 407-423.  
18567851 J.Lindstrom, J.Luo, and A.Kuryatov (2008).
Myasthenia gravis and the tops and bottoms of AChRs: antigenic structure of the MIR and specific immunosuppression of EAMG using AChR cytoplasmic domains.
  Ann N Y Acad Sci, 1132, 29-41.  
14592862 J.M.Lindstrom (2003).
Nicotinic acetylcholine receptors of muscles and nerves: comparison of their structures, functional roles, and vulnerability to pathology.
  Ann N Y Acad Sci, 998, 41-52.  
12695308 T.K.Sixma, and A.B.Smit (2003).
Acetylcholine binding protein (AChBP): a secreted glial protein that provides a high-resolution model for the extracellular domain of pentameric ligand-gated ion channels.
  Annu Rev Biophys Biomol Struct, 32, 311-334.  
12436428 J.Lindstrom (2002).
Autoimmune diseases involving nicotinic receptors.
  J Neurobiol, 53, 656-665.  
The most recent references are shown first. Citation data come partly from CiteXplore and partly from an automated harvesting procedure. Note that this is likely to be only a partial list as not all journals are covered by either method. However, we are continually building up the citation data so more and more references will be included with time.

 

spacer

spacer